Every 8-K that TEVA PHARM INDUS LTD (TEVJF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TEVJF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEVJF filings page.
Teva Pharmaceutical Industries Ltd. (TEVA) announced multiple new senior note issuances totaling €1.5 billion and $3.2 billion through its subsidiaries Teva Finance II, III and IV on September 16, 2026. The euro tranches are €1,000,000,000 of 4.250% Senior Notes due 2033 and €500,000,000 of 4.625% Senior Notes due 2036, and the U.S. dollar tranches are $1,200,000,000 of 5.250% Senior Notes due 2032, $1,000,000,000 of 5.500% Senior Notes due 2034 and $1,000,000,000 of 5.750% Senior Notes due 2037.
Teva intends to use net proceeds primarily to fund conditional redemptions of several higher‑coupon existing notes, including 6.750% Senior Notes due 2028 and multiple sustainability‑linked notes, and for general corporate purposes. The new notes are senior unsecured obligations, fully and unconditionally guaranteed on a senior unsecured basis by Teva, with standard covenants, change‑of‑control repurchase rights at 101% of principal, and make‑whole and par call redemption provisions by series.
Teva Pharmaceutical Industries Ltd. (TEVA) reports that on September 14, 2026 its ordinary shares began trading on the New York Stock Exchange under the ticker “TEVA,” replacing its American depositary shares (ADSs). On the same date, Teva’s ADS program terminated, with each ADS exchanged for one ordinary share.
The company’s ordinary shares continue to trade on the Tel Aviv Stock Exchange under the symbol “TEVA.” Additional details are available via the investor relations section of Teva’s website.
Teva Pharmaceutical Industries Ltd. (TEVA) announced that its Dutch financing subsidiaries priced a multi‑tranche offering of approximately $4.9 billion (equivalent) in senior notes, guaranteed on a senior unsecured basis by Teva. The new Securities comprise €1,000,000,000 of 4.250% notes due 2033, €500,000,000 of 4.625% notes due 2036, $1,000,000,000 of 5.500% notes due 2034, $1,000,000,000 of 5.750% notes due 2037, and $1,200,000,000 of 5.250% notes due 2032, each priced slightly below par. Settlement is expected on or about September 16, 2026, subject to customary closing conditions.
Teva expects to use the net proceeds, together with cash on hand, to fund conditional redemptions of several higher‑coupon outstanding series, including all 6.750% Senior Notes due 2028, all 7.875% and 7.375% Sustainability‑Linked Senior Notes due 2029, up to $450,000,000 of 4.750% Sustainability‑Linked Notes due 2027, and up to €1,150,000,000 of 4.375% Sustainability‑Linked Notes due 2030, as well as to pay related fees and, to the extent of any remaining proceeds, for general corporate purposes, including repayment of other debt.
Teva Pharmaceutical Industries Limited (TEVA) reports a change in how it presents its operating segments and has retrospectively recast prior disclosures from its Form 10‑K for the year ended December 31, 2025. Effective January 1, 2026, Anda, Teva’s U.S. distribution business, is no longer part of the United States segment and is reported within Other Activities.
The recast updates segment information in Business, Management’s Discussion and Analysis, and Financial Statements and Supplementary Data to align with Teva’s Pivot to Growth strategy and internal reporting. Teva states that consolidated balance sheets, income statements, cash flows and other disclosures from the original 2025 Form 10‑K are unchanged, and no new events after that report are reflected.
Teva Pharmaceutical Industries Ltd. (TEVA) reported a material modification to the rights of its security holders by amending its deposit agreement and updating the form of American depositary receipt in connection with terminating its American depositary share (ADS) program. Each ADS represents one ordinary share, par value NIS 0.10 per share.
The amendment establishes a mandatory exchange under which each ADS will be exchanged for one ordinary share, and all outstanding ADSs will be cancelled in exchange for an equal number of economically equivalent ordinary shares listed on the New York Stock Exchange. The termination of the ADS program is expected to occur at the open of business (New York time) on September 14, 2026.
Teva Pharmaceutical Industries reported Q2 2026 net revenues of $4.14 billion, down 1% year over year, as lower U.S. generics, especially lenalidomide, offset strong growth in key innovative brands. AUSTEDO, AJOVY and UZEDY together generated over $1 billion, growing 43% in local currency.
Teva recorded a GAAP net loss of $576 million, or $0.49 per share, driven by $724 million of acquired IPR&D and $2 million of operating expenses from the $700 million Emalex Biosciences acquisition. Non‑GAAP net income was $21 million with diluted EPS of $0.02; adjusted EBITDA was $474 million versus $1.23 billion a year earlier.
Operating cash flow improved to $411 million and free cash flow to $622 million. For 2026, Teva maintains guidance for revenues of $16.5–$16.85 billion, non‑GAAP EPS of $1.91–$2.11 and free cash flow of $2.0–$2.4 billion, while raising its outlook for AUSTEDO, AJOVY and UZEDY to about $3.7 billion combined. The company also plans to replace its ADS program with a direct NYSE listing of ordinary shares and noted an upgrade of its corporate credit rating to investment grade BBB‑.
Teva Pharmaceutical Industries Limited reported results of its annual shareholder meeting held on May 28, 2026. Shareholders elected Dr. Sol J. Barer to the Board to serve until the 2029 annual meeting, with 627,816,662 votes for and 245,921,571 against.
Shareholders also approved, on a non-binding advisory basis, the compensation of Teva’s named executive officers, with 795,976,042 votes for and 77,082,847 against. In addition, they approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as independent registered public accounting firm through the 2027 annual meeting.
Teva Pharmaceutical Industries reported first quarter 2026 revenues of $3.98 billion, up 2% in U.S. dollars but down 3% in local currencies, as strong growth in key innovative brands offset weaker generics, especially lower U.S. sales of lenalidomide capsules.
GAAP diluted EPS rose to $0.31 from $0.18, while non-GAAP diluted EPS edged up to $0.53 from $0.52, supported by higher gross profit and lower intangible impairments. Innovative products AUSTEDO, AJOVY and UZEDY generated $838 million collectively and grew 41% year over year in local currency.
Teva maintained its 2026 outlook, guiding to revenues of $16.4–$16.8 billion, non-GAAP operating income of $3.8–$4.0 billion and free cash flow of $2.0–$2.4 billion, including the impact of its agreement to acquire Emalex Biosciences for $700 million upfront plus up to $200 million in milestones and royalties tied to ecopipam for pediatric Tourette syndrome.
Teva Pharmaceutical Industries Limited furnished an update on its business performance by submitting an 8-K tied to its latest earnings release. On January 28, 2026, the company issued a press release detailing financial results for the period ended December 31, 2025, covering both full-year 2025 and fourth quarter performance. This press release is provided as Exhibit 99.1 and is incorporated by reference into the report, but the underlying financial figures and metrics appear only in the exhibit itself. The 8-K specifies that this earnings information is being furnished rather than filed, which affects how it is treated under U.S. securities laws.
Teva Pharmaceutical Industries Limited furnished an update on its expected performance for the 2025 fiscal year in connection with its presentation at the 44th Annual J.P. Morgan Healthcare Conference. On January 11, 2026, the company issued a press release outlining these expectations ahead of its January 13, 2026 conference presentation, and attached that release as an exhibit. The information is being provided to regulators for disclosure purposes and is expressly designated as furnished rather than filed under U.S. securities laws.
Teva Pharmaceutical Industries Limited has amended its senior unsecured sustainability-linked revolving credit agreement to extend the stated maturity date of the lenders’ commitments and loans by one year, from April 29, 2027 to April 29, 2028. This extension is the second one-year extension permitted under the original April 29, 2022 agreement and helps keep this revolving credit facility available for a longer period.
The amendment also updates key financial covenants. The Company’s maximum permitted leverage ratio for Q4 2025 and thereafter is set at 4.25x, with potential increases if Teva completes or starts certain material transactions. If Teva achieves Investment Grade Status and no event of default is continuing, the maximum leverage and minimum interest cover ratio covenants will no longer apply; if Investment Grade Status is later lost or an event of default occurs, these covenants will be reinstated for future testing dates.
Teva Pharmaceutical Industries Limited furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the period ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company states the information is being furnished, not filed, under the Exchange Act, which means it is not subject to Section 18 liability, unless specifically incorporated by reference elsewhere.